PitchSend

Investor Presentaiton

sanofi Only Sanofi has the potential to offer Best-in-Class protection for all targeted ages Beyfortus Best-in-Class for All Infant Protection in first season SPO125 PROFILE First-in-Class vaccine for second season onwards SPO256 First-in-Class with RSV-hMPV- PIV mRNA combination Ready for launch 39 Vaccines Investor Event NEXT STEPS Phase 3 start in H1 2024 Target submission in 2026 Phase 2b RSV & Phase 1/2 combo start in 2023 Target submission for combo in 2026+

View entire presentation